These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2910508)

  • 1. A new anticancer agent (LY186641) interferes with creatinine assay.
    Bonnay MM; Recondo G; Gouyette AJ; Armand JP
    Cancer Chemother Pharmacol; 1989; 23(2):119-20. PubMed ID: 2910508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans.
    Hande KR; Kuttesch J; Hamilton M; Satterlee W; Jackson L; Grindey G; Hainsworth JD
    Cancer Res; 1990 Jul; 50(13):3910-4. PubMed ID: 2354440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641).
    Hainsworth JD; Hande KR; Satterlee WG; Kuttesch J; Johnson DH; Grindey G; Jackson LE; Greco FA
    Cancer Res; 1989 Sep; 49(18):5217-20. PubMed ID: 2766290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of a novel diarylsulfonylurea anticancer agent.
    Taylor CW; Alberts DS; Ketcham MA; Satterlee WG; Holdsworth MT; Plezia PM; Peng YM; McCloskey TM; Roe DJ; Hamilton M
    J Clin Oncol; 1989 Nov; 7(11):1733-40. PubMed ID: 2809686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel diarylsulfonylurea derivatives as potent antimitotic agents.
    Kim S; Park JH; Koo SY; Kim JI; Kim MH; Kim JE; Jo K; Choi HG; Lee SB; Jung SH
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6075-8. PubMed ID: 15546733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of diarylsulfonylurea antitumor agents on the function of mitochondria isolated from rat liver and GC3/c1 cells.
    Rush GF; Rinzel S; Boder G; Heim RA; Toth JE; Ponsler GD
    Biochem Pharmacol; 1992 Dec; 44(12):2387-94. PubMed ID: 1472104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys, and dogs.
    Ehlhardt WJ; Sullivan HR; Wood PG; Woodland JM; Hamilton M; Hamilton C; Cornpropst D; Grindey GB; Worzalla JF; Bewley JR
    J Pharm Sci; 1993 Jul; 82(7):683-8. PubMed ID: 8360840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and disposition of the anticancer agent sulofenur in mouse, rat, monkey, and human.
    Ehlhardt WJ
    Drug Metab Dispos; 1991; 19(2):370-5. PubMed ID: 1676639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of sulofenur (LY186641) in measurable metastatic renal cancer.
    Weinerman B; Eisenhauer E; Stewart D; Mertens W; Tannock I; Venner P; Spaulding R
    Ann Oncol; 1992 Jan; 3(1):83-4. PubMed ID: 1606075
    [No Abstract]   [Full Text] [Related]  

  • 10. [Flavone acetic acid and LY 186641 interfere in various ways in Jaffé's reaction].
    Bonnay M; Gouyette A; Chabot G; Recondo G; Armand JP
    Bull Cancer; 1989; 76(8):839-41. PubMed ID: 2620109
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent Development of Sulfonyl or Sulfonamide Hybrids as Potential Anticancer Agents: A Key Review.
    Rakesh KP; Wang SM; Leng J; Ravindar L; Asiri AM; Marwani HM; Qin HL
    Anticancer Agents Med Chem; 2018; 18(4):488-505. PubMed ID: 29110622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interference by sulfonylurea drugs with the Jaffé method for creatinine.
    Roach NA; Kroll MH; Elin RJ
    Clin Chim Acta; 1985 Oct; 151(3):301-5. PubMed ID: 4053390
    [No Abstract]   [Full Text] [Related]  

  • 13. Glutathione and mercapturic acid conjugates of sulofenur and their activity against a human colon cancer cell line.
    Guan X; Hoffman BN; McFarland DC; Gilkerson KK; Dwivedi C; Erickson AK; Bebensee S; Pellegrini J
    Drug Metab Dispos; 2002 Mar; 30(3):331-5. PubMed ID: 11854154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Separation of resistance to antitumor diarylsulfonylurea agents from collateral sensitivity to mitochondrial toxins.
    Shu LL; Houghton PJ
    Mol Pharmacol; 1996 Apr; 49(4):595-601. PubMed ID: 8609886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-resistance to antitumor diarylsulfonylureas and collateral sensitivity to mitochondrial toxins in a human cell line selected for resistance to the antitumor agent N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea.
    Sosinski J; Thakar JH; Germain GS; Dias P; Harwood FC; Kuttesch JF; Houghton PJ
    Mol Pharmacol; 1994 May; 45(5):962-70. PubMed ID: 7910660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma.
    Houghton PJ; Houghton JA; Myers L; Cheshire P; Howbert JJ; Grindey GB
    Cancer Chemother Pharmacol; 1989; 25(2):84-8. PubMed ID: 2598403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impermeant antitumor sulfonylurea conjugates that inhibit plasma membrane NADH oxidase and growth of HeLa cells in culture. Identification of binding proteins from sera of cancer patients.
    Kim C; MacKellar WC; Cho NM; Byrn SR; Morré DJ
    Biochim Biophys Acta; 1997 Mar; 1324(2):171-81. PubMed ID: 9092704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton release from HeLa cells and alkalization of cytoplasm induced by diferric transferrin or ferricyanide and its inhibition by the diarylsulfonylurea antitumor drug N-(4-methylphenylsulfonyl)-N'-(4-cholorophenyl) urea (LY181984).
    Sun E; Lawrence J; Morré DM; Sun I; Crane FL; MacKellar WC; Morré DJ
    Biochem Pharmacol; 1995 Oct; 50(9):1461-8. PubMed ID: 7503797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea, a novel agent equally cytotoxic to nonproliferating human colon adenocarcinoma cells.
    Houghton PJ; Bailey FC; Germain GS; Grindey GB; Witt BC; Houghton JA
    Cancer Res; 1990 Jan; 50(2):318-22. PubMed ID: 2295071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidiabetic effect of novel benzenesulfonylureas as PPAR-γ agonists and their anticancer effect.
    Kharbanda C; Alam MS; Hamid H; Javed K; Dhulap A; Bano S; Ali Y
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4601-5. PubMed ID: 26384286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.